Literature DB >> 10770955

Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor.

A Truneh1, S Sharma, C Silverman, S Khandekar, M P Reddy, K C Deen, M M McLaughlin, S M Srinivasula, G P Livi, L A Marshall, E S Alnemri, W V Williams, M L Doyle.   

Abstract

TRAIL is a member of the tumor necrosis factor (TNF) family of cytokines which induces apoptotic cell death in a variety of tumor cell lines. It mediates its apoptotic effects through one of two receptors, DR4 and DR5, which are members of of the TNF receptor family, and whose cytoplasmic regions contain death domains. In addition, TRAIL also binds to 3 "decoy" receptors, DcR2, a receptor with a truncated death domain, DcR1, a glycosylphosphatidylinositol-anchored receptor, and OPG a secreted protein which is also known to bind to another member of the TNF family, RANKL. However, although apoptosis depends on the expression of one or both of the death domain containing receptors DR4 and/or DR5, resistance to TRAIL-induced apoptosis does not correlate with the expression of the "decoy" receptors. Previously, TRAIL has been described to bind to all its receptors with equivalent high affinities. In the present work, we show, by isothermal titration calorimetry and competitive enzyme-linked immunosorbent assay, that the rank order of affinities of TRAIL for the recombinant soluble forms of its receptors is strongly temperature dependent. Although DR4, DR5, DcR1, and OPG show similar affinities for TRAIL at 4 degrees C, their rank-ordered affinities are substantially different at 37 degrees C, with DR5 having the highest affinity (K(D) </= 2 nm) and OPG having the weakest (K(D) = 400 nm). Preferentially enhanced binding of TRAIL to DR5 was also observed at the cell surface. These results reveal that the rank ordering of affinities for protein-protein interactions in general can be a strong function of temperature, and indicate that sizeable, but hitherto unobserved, TRAIL affinity differences exist at physiological temperature, and should be taken into account in order to understand the complex physiological and/or pathological roles of TRAIL.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10770955     DOI: 10.1074/jbc.M910438199

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  71 in total

Review 1.  Resistance to TRAIL and how to surmount it.

Authors:  Danijela Maksimovic-Ivanic; Stanislava Stosic-Grujicic; Ferdinando Nicoletti; Sanja Mijatovic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

2.  Role of RANK ligand in mediating increased bone resorption in early postmenopausal women.

Authors:  Guitty Eghbali-Fatourechi; Sundeep Khosla; Arunik Sanyal; William J Boyle; David L Lacey; B Lawrence Riggs
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

Review 3.  Hepatocyte death: a clear and present danger.

Authors:  Harmeet Malhi; Maria Eugenia Guicciardi; Gregory J Gores
Journal:  Physiol Rev       Date:  2010-07       Impact factor: 37.312

4.  Binding Studies of TNF Receptor Superfamily (TNFRSF) Receptors on Intact Cells.

Authors:  Isabell Lang; Simone Füllsack; Agnes Wyzgol; Andrea Fick; Johannes Trebing; José Antonio Carmona Arana; Viktoria Schäfer; Daniela Weisenberger; Harald Wajant
Journal:  J Biol Chem       Date:  2015-12-31       Impact factor: 5.157

5.  The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl.

Authors:  Jennifer L Dine; Ciara C O'Sullivan; Donna Voeller; Yoshimi E Greer; Kathryn J Chavez; Catherine M Conway; Sarah Sinclair; Brandon Stone; Laleh Amiri-Kordestani; Anand S Merchant; Stephen M Hewitt; Seth M Steinberg; Sandra M Swain; Stanley Lipkowitz
Journal:  Breast Cancer Res Treat       Date:  2016-01-12       Impact factor: 4.872

6.  Zyflamend sensitizes tumor cells to TRAIL-induced apoptosis through up-regulation of death receptors and down-regulation of survival proteins: role of ROS-dependent CCAAT/enhancer-binding protein-homologous protein pathway.

Authors:  Ji Hye Kim; Byoungduck Park; Subash C Gupta; Ramaswamy Kannappan; Bokyung Sung; Bharat B Aggarwal
Journal:  Antioxid Redox Signal       Date:  2011-12-15       Impact factor: 8.401

7.  Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.

Authors:  C Van Poznak; S S Cross; M Saggese; C Hudis; K S Panageas; L Norton; R E Coleman; I Holen
Journal:  J Clin Pathol       Date:  2006-01       Impact factor: 3.411

8.  RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor.

Authors:  Christopher A Nelson; Julia T Warren; Michael W-H Wang; Steven L Teitelbaum; Daved H Fremont
Journal:  Structure       Date:  2012-10-02       Impact factor: 5.006

9.  Decreased affinity of recombinant human tumor necrosis factor-related apoptosis-inducing ligand (rhTRAIL) D269H/E195R to osteoprotegerin (OPG) overcomes TRAIL resistance mediated by the bone microenvironment.

Authors:  Matthieu C J Bosman; Carlos R Reis; Jan J Schuringa; Edo Vellenga; Wim J Quax
Journal:  J Biol Chem       Date:  2013-11-26       Impact factor: 5.157

10.  Detachment of esophageal carcinoma cells from extracellular matrix causes relocalization of death receptor 5 and apoptosis.

Authors:  Guang-Chao Liu; Jun Zhang; Shi-Gui Liu; Rong Gao; Zhang-Fu Long; Ke Tao; Yuan-Fang Ma
Journal:  World J Gastroenterol       Date:  2009-02-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.